Angela M Davies

Summary

Affiliation: OSI Pharmaceuticals
Country: USA

Publications

  1. ncbi Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer
    Angela M Davies
    University of California, Davis Cancer Center, Sacramento, California 95817, USA
    J Thorac Oncol 2:1112-6. 2007
  2. ncbi Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation
    Angela M Davies
    University of California Davis Cancer Center, Sacramento, California, USA
    J Thorac Oncol 4:862-8. 2009
  3. ncbi Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339)
    Angela M Davies
    Department of Hematology Oncology, University of California, Davis Cancer Center, Sacramento, California, USA
    J Thorac Oncol 4:87-92. 2009
  4. ncbi The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study
    Angela M Davies
    Division of Hematology and Oncology, Davis Cancer Center, University of California, Sacramento, California 95817, USA
    J Thorac Oncol 3:68-74. 2008
  5. ncbi Proteasome inhibition in small-cell lung cancer: preclinical rationale and clinical applications
    Primo N Lara
    University of California Davis Cancer Center, Sacramento, 95817, USA
    Clin Lung Cancer 7:S67-71. 2005
  6. ncbi Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer
    Angela M Davies
    Division of Hematology Oncology, University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 7:385-8. 2006
  7. ncbi EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer
    Philip C Mack
    Division of Hematology and Oncology, University of California, Davis Cancer Center, Sacramento, California 95817, USA
    J Thorac Oncol 4:1466-72. 2009
  8. ncbi Bortezomib-based combinations in the treatment of non-small-cell lung cancer
    Angela M Davies
    University of California Davis Cancer Center, Sacramento, 95817, USA
    Clin Lung Cancer 7:S59-63. 2005
  9. ncbi Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327)
    Primo N Lara
    University of California, Davis Cancer Center, Sacramento, CA 95817, USA
    J Thorac Oncol 1:996-1001. 2006
  10. ncbi Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies
    David R Gandara
    University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 8:S61-7. 2007

Detail Information

Publications26

  1. ncbi Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer
    Angela M Davies
    University of California, Davis Cancer Center, Sacramento, California 95817, USA
    J Thorac Oncol 2:1112-6. 2007
    ..We examined the safety and tolerability of pemetrexed in combination with two different schedules of bortezomib in patients with advanced solid tumors...
  2. ncbi Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation
    Angela M Davies
    University of California Davis Cancer Center, Sacramento, California, USA
    J Thorac Oncol 4:862-8. 2009
    ..Pharmacodynamic separation by intermittent delivery of epidermal growth factor receptor tyrosine kinase inhibitors with chemotherapy may increase efficacy by overcoming hypothesized antagonism...
  3. ncbi Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339)
    Angela M Davies
    Department of Hematology Oncology, University of California, Davis Cancer Center, Sacramento, California, USA
    J Thorac Oncol 4:87-92. 2009
    ..This phase II study of bortezomib in combination with gemcitabine/carboplatin was conducted in chemotherapy-naive advanced NSCLC patients to assess efficacy and safety...
  4. ncbi The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study
    Angela M Davies
    Division of Hematology and Oncology, Davis Cancer Center, University of California, Sacramento, California 95817, USA
    J Thorac Oncol 3:68-74. 2008
    ..The combination of gemcitabine and carboplatin is an accepted first-line treatment for advanced NSCLC. We conducted a phase I study of gemcitabine and carboplatin in combination with bortezomib...
  5. ncbi Proteasome inhibition in small-cell lung cancer: preclinical rationale and clinical applications
    Primo N Lara
    University of California Davis Cancer Center, Sacramento, 95817, USA
    Clin Lung Cancer 7:S67-71. 2005
    ..Bortezomib is a proteasome inhibitor that can decrease Bcl-2 expression through diminished IkappaB degradation. Efforts to promote apoptosis in SCLC through the integration of bortezomib into therapy are under way...
  6. ncbi Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer
    Angela M Davies
    Division of Hematology Oncology, University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 7:385-8. 2006
    ..Herein we provide the preclinical and clinical rationale for studies examining the concept of pharmacodynamic separation as a means for overcoming hypothesized antagonism of EGFR TKIs and chemotherapy...
  7. ncbi EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer
    Philip C Mack
    Division of Hematology and Oncology, University of California, Davis Cancer Center, Sacramento, California 95817, USA
    J Thorac Oncol 4:1466-72. 2009
    ..We hypothesized that analysis of plasma for EGFR and KRAS mutations from shed tumor DNA would have clinical utility...
  8. ncbi Bortezomib-based combinations in the treatment of non-small-cell lung cancer
    Angela M Davies
    University of California Davis Cancer Center, Sacramento, 95817, USA
    Clin Lung Cancer 7:S59-63. 2005
    ..This article will review the rationale and preclinical data supporting bortezomib combinations and the clinical trials with bortezomib alone and in combination in NSCLC to date...
  9. ncbi Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327)
    Primo N Lara
    University of California, Davis Cancer Center, Sacramento, CA 95817, USA
    J Thorac Oncol 1:996-1001. 2006
    ..We conducted a phase II trial of PS-341 in previously treated patients with platinum-sensitive and -refractory extensive stage SCLC to determine response rate, toxicity, and survival...
  10. ncbi Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies
    David R Gandara
    University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 8:S61-7. 2007
    ....
  11. ncbi Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation
    Christopher M Mahaffey
    University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 8:548-53. 2007
    ..We hypothesized that the lack of benefit resulted from a negative interaction between chemotherapy and EGFR TKIs...
  12. ncbi Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712
    Angela M Davies
    University of California, Davis, Sacramento, CA, USA
    J Clin Oncol 24:5242-6. 2006
    ..This study evaluated adding consolidation paclitaxel after chemoradiotherapy for a similar patient cohort...
  13. ncbi Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial
    Primo N Lara
    University of California, Davis Cancer Center, Sacramento, California 95817, USA
    J Thorac Oncol 1:126-34. 2006
    ..This phase I study was performed to determine the dose-limiting toxicity and maximum tolerated dose (MTD) of docetaxel in combination with bortezomib in patients with advanced non-small cell lung cancer (NSCLC) or other solid tumors...
  14. ncbi Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition
    David R Gandara
    University of California Davis Cancer Center, Sacramento, California, USA
    Clin Cancer Res 10:4205s-4209s. 2004
    ..These studies provide a biological rationale for investigating BAC as a model of predictive markers of EGFR inhibition...
  15. ncbi Predictive molecular markers: has the time come for routine use in lung cancer?
    Angela M Davies
    Division of Hematology Oncology, Department of Internal Medicine, University of California Davis Cancer Center, Sacramento, California, USA
    J Natl Compr Canc Netw 2:125-31. 2004
    ..To date, none of these markers can be recommended for routine use in clinical practice...
  16. ncbi Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study
    Angela M Davies
    Davis Cancer Center, University of California, 4501 X Street, Suite 3016, Sacramento, CA 95817, USA
    Invest New Drugs 25:351-5. 2007
    ....
  17. ncbi Incorporating bortezomib into the treatment of lung cancer
    Angela M Davies
    UC Davis Cancer Center, University of California, Sacramento, California 95817, USA
    Clin Cancer Res 13:s4647-51. 2007
    ..Ongoing studies are focused on optimizing the scheduling of bortezomib with chemotherapy, investigating its combination with targeted agents and radiation, and examining its efficacy in a specific subgroup, bronchioloalveolar carcinoma...
  18. ncbi Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trial
    Randeep Sangha
    Division of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada
    J Thorac Oncol 6:2112-9. 2011
    ....
  19. ncbi Second-line treatment for advanced-stage non-small-cell lung cancer: current and future options
    Cheryl Ho
    Division of Hematology and Oncology, University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 7:S118-25. 2006
    ..Research efforts continue to focus on identifying molecular markers and corresponding clinical features that will allow physicians to individualize patients' therapy...
  20. ncbi Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer
    Philip C Mack
    Division of Hematology Oncology, Department of Internal Medicine, University of California Davis Cancer Center, 4501 X Street, Sacramento, CA 95817, USA
    Lung Cancer 41:S89-96. 2003
    ..PS-341 is currently in phase I/II clinical development in lung cancer. This paper will review the pre-clinical and clinical experience with PS-341 as it relates to lung cancer...
  21. ncbi Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer
    Melinda M Mortenson
    Division of Surgical Oncology, Suite 3010, University of California, Davis Cancer Center, 4501 X Street, Sacramento, CA 95817, USA
    Lung Cancer 49:163-70. 2005
    ..These data provide the necessary laboratory background for further investigation of bortezomib in the treatment of SCLC...
  22. ncbi Treatment of extensive small cell lung cancer
    Angela M Davies
    University of California-Davis Cancer Center, 4501 X Street, Suite 3016, Sacramento, CA 95817, USA
    Hematol Oncol Clin North Am 18:373-85. 2004
  23. ncbi Aurora kinase inhibitors: a new class of targeted drugs in cancer
    Oliver Gautschi
    University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Clin Lung Cancer 8:93-8. 2006
    ..This article reviews the biology of aurora kinases, their potential role in the treatment of lung cancer, and challenges in the clinical development of this unique class of antineoplastic agents...
  24. ncbi Treatment of recurrent small cell lung cancer
    Angela M Davies
    University of California at Davis Cancer Center, 4501 X Street, Suite 3016, Sacramento, CA 95817, USA
    Hematol Oncol Clin North Am 18:387-416. 2004
  25. ncbi Docetaxel in non-small cell lung cancer: a review
    Angela M Davies
    Division of Hematology Oncology, Department of Internal Medicine, University of California Davis Cancer Center, Sacramento, CA 95817, USA
    Expert Opin Pharmacother 4:553-65. 2003
    ..This paper will review the pharmacology, preclinical, clinical and pharmacoeconomic data supporting the use of docetaxel in the treatment NSCLC...
  26. ncbi Commentary: Oncologic drugs in patients with organ dysfunction: a summary
    Diana Superfin
    University of California Davis Cancer Center, 4501 X Street, Sacramento, California 95817, USA
    Oncologist 12:1070-83. 2007
    ....